The DPP9 Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the DPP9 gene. This loss-of-function model enables investigation of DPP9-dependent processes in an epithelial cervical adenocarcinoma background. The polyclonal format preserves heterogeneous gene-editing outcomes while uniformly eliminating DPP9 protease activity across the pool, providing a robust tool for studying dipeptidyl peptidase 9 biology in a well-characterized cancer model.
The host HeLa cell line is an immortalized human cervical adenocarcinoma positive for HPV18, widely employed for cancer research. Its epithelial origin and transformation by viral oncoproteins E6 and E7 disrupt p53 and Rb pathways, providing a deregulated proliferative context for studying pathways involved in tumorigenesis, metastasis, and drug response.
DPP9 is a serine protease that removes N-terminal dipeptides from substrates with Pro or Ala at the penultimate position, influencing immune regulation, apoptosis, and cell adhesion. DPP9 is activated by IFN-?? and TNF-?? and functions downstream of NF-??B. It processes neuropeptide Y (NPY) and glucagon-like peptide-1 (GLP-1), and its activity modulates CXCL10 expression, linking protease function to inflammatory signaling. DPP9 interacts with DPP8 and forms dimers. Loss of DPP9 leads to substrate accumulation, altered peptide hormone degradation, and impacts on immune and apoptotic pathways.
In HeLa cells, DPP9 knockout impacts tumor-relevant phenotypes. DPP9 modulates cell adhesion and migration, contributing to metastatic potential. Its role in antigen presentation may affect immune recognition, while altered apoptosis signaling could influence chemosensitivity. This model enables exploration of DPP9’s functions in cervical cancer progression and its interplay with HPV-mediated oncogenesis.
These polyclonal cells are suited for cancer biology, immune regulation, protease function analysis, and drug target validation. Representative assays include DPP enzymatic activity with Gly-Pro-AMC, western blot, RT-qPCR, apoptosis and migration assays, flow cytometry, and CXCL10 ELISA. Cell viability screens and cytokine profiling further support mechanistic and therapeutic studies. For additional inquiries or to place an order, please contact Ascent Research.
